🚀 VC round data is live in beta, check it out!
Aquestive Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aquestive Therapeutics and similar public comparables like Invivyd, Agomab Therapeutics, 4D Molecular Therapeutics, Immix Biopharma and more.
Aquestive Therapeutics Overview
About Aquestive Therapeutics
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Founded
2017
HQ
Employees
142
Website
Sectors
Financials (LTM)
EV
$430M
Aquestive Therapeutics Financials
Aquestive Therapeutics reported last 12-month revenue of $46M and negative EBITDA of ($45M).
In the same LTM period, Aquestive Therapeutics generated $27M in gross profit, ($45M) in EBITDA losses, and had net loss of ($77M).
Revenue (LTM)
Aquestive Therapeutics P&L
In the most recent fiscal year, Aquestive Therapeutics reported revenue of $45M and EBITDA of ($50M).
Aquestive Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $46M | XXX | $45M | XXX | XXX | XXX |
| Gross Profit | $27M | XXX | $26M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | ($45M) | XXX | ($50M) | XXX | XXX | XXX |
| EBITDA Margin | (100%) | XXX | (112%) | XXX | XXX | XXX |
| EBIT Margin | (143%) | XXX | (160%) | XXX | XXX | XXX |
| Net Profit | ($77M) | XXX | ($84M) | XXX | XXX | XXX |
| Net Margin | (169%) | XXX | (188%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aquestive Therapeutics Stock Performance
Aquestive Therapeutics has current market cap of $509M, and enterprise value of $430M.
Market Cap Evolution
Aquestive Therapeutics' stock price is $4.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $430M | $509M | -0.2% | XXX | XXX | XXX | $-0.69 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAquestive Therapeutics Valuation Multiples
Aquestive Therapeutics trades at 9.5x EV/Revenue multiple, and (9.5x) EV/EBITDA.
EV / Revenue (LTM)
Aquestive Therapeutics Financial Valuation Multiples
As of April 11, 2026, Aquestive Therapeutics has market cap of $509M and EV of $430M.
Equity research analysts estimate Aquestive Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aquestive Therapeutics has a P/E ratio of (6.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $509M | XXX | $509M | XXX | XXX | XXX |
| EV (current) | $430M | XXX | $430M | XXX | XXX | XXX |
| EV/Revenue | 9.5x | XXX | 9.7x | XXX | XXX | XXX |
| EV/EBITDA | (9.5x) | XXX | (8.7x) | XXX | XXX | XXX |
| EV/EBIT | (6.6x) | XXX | (6.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 15.8x | XXX | 16.6x | XXX | XXX | XXX |
| P/E | (6.6x) | XXX | (6.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aquestive Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aquestive Therapeutics Margins & Growth Rates
Aquestive Therapeutics' revenue in the last 12 month grew by 20%.
Aquestive Therapeutics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.7M for the same period.
Aquestive Therapeutics' rule of 40 is (64%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aquestive Therapeutics' rule of X is (52%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Aquestive Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | (100%) | XXX | (112%) | XXX | XXX | XXX |
| EBITDA Growth | (26%) | XXX | (31%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (64%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (52%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 148% | XXX | 150% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 36% | XXX | 39% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 218% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aquestive Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Invivyd | XXX | XXX | XXX | XXX | XXX | XXX |
| Agomab Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| 4D Molecular Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Immix Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Polaris Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aquestive Therapeutics M&A Activity
Aquestive Therapeutics acquired XXX companies to date.
Last acquisition by Aquestive Therapeutics was on XXXXXXXX, XXXXX. Aquestive Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aquestive Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAquestive Therapeutics Investment Activity
Aquestive Therapeutics invested in XXX companies to date.
Aquestive Therapeutics made its latest investment on XXXXXXXX, XXXXX. Aquestive Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aquestive Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aquestive Therapeutics
| When was Aquestive Therapeutics founded? | Aquestive Therapeutics was founded in 2017. |
| Where is Aquestive Therapeutics headquartered? | Aquestive Therapeutics is headquartered in United States. |
| How many employees does Aquestive Therapeutics have? | As of today, Aquestive Therapeutics has over 142 employees. |
| Who is the CEO of Aquestive Therapeutics? | Aquestive Therapeutics' CEO is Daniel Barber. |
| Is Aquestive Therapeutics publicly listed? | Yes, Aquestive Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Aquestive Therapeutics? | Aquestive Therapeutics trades under AQST ticker. |
| When did Aquestive Therapeutics go public? | Aquestive Therapeutics went public in 2018. |
| Who are competitors of Aquestive Therapeutics? | Aquestive Therapeutics main competitors are Invivyd, Agomab Therapeutics, 4D Molecular Therapeutics, Immix Biopharma. |
| What is the current market cap of Aquestive Therapeutics? | Aquestive Therapeutics' current market cap is $509M. |
| What is the current revenue of Aquestive Therapeutics? | Aquestive Therapeutics' last 12 months revenue is $46M. |
| What is the current revenue growth of Aquestive Therapeutics? | Aquestive Therapeutics revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Aquestive Therapeutics? | Current revenue multiple of Aquestive Therapeutics is 9.5x. |
| Is Aquestive Therapeutics profitable? | No, Aquestive Therapeutics is not profitable. |
| What is the current EBITDA of Aquestive Therapeutics? | Aquestive Therapeutics has negative EBITDA and is not profitable. |
| What is Aquestive Therapeutics' EBITDA margin? | Aquestive Therapeutics' last 12 months EBITDA margin is (100%). |
| What is the current EV/EBITDA multiple of Aquestive Therapeutics? | Current EBITDA multiple of Aquestive Therapeutics is (9.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.